major depressive disorder

Vilazodone (SB659746A) is a selective serotonin (5-HT) reuptake inhibitor (SSRI) and a 5-HT-1A receptor partial agonist, with antidepressant and anti-anxiety activities. Vilazodone inhibits the reuptake of serotonin from the synaptic cleft while stimulating the release of 5-HT into the synaptic cleft. This increases the concentration of 5-HT in the synaptic cleft and potentiates serotonergic neurotransmission in the central nervous system.

Imiloxan (RS-21361) is an α2 adrenergic receptor antagonist used in the treatment of major depressive disorder.

Liafensine(BMS-820836) is a novel and selective triple monoamine reuptake inhibitor with inhibitory effects on the reuptake of serotonin, norepinephrine, and dopamine for the study of major depressive disorder and central nervous system disorders.

Zalospirone is a 5-HT1A receptor agonist that can be used to study anxiety disorders and major depressive disorder.

Venlafaxine (Wy 45030), an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI), is used to treat major generalised anxiety disorder (GAD), depressive disorder (MDD), panic disorder and social phobia.

Vilazodone Hydrochloride (EMD 68843) , a partial agonist of 5-HT1A receptors and specific serotonin reuptake inhibitor (SSRI), is utilized in treating of the major depressive disorder.

ZZL-7 is a fast-onset antidepressant agent that disrupts the interaction between neuronal nitric oxide synthase (nNOS) and the serotonin transporter (SERT) in the dorsal raphe nucleus (DRN). It easily crosses the blood-brain barrier and has research value in major depressive disorder (MDD).

CGP 25454A is a selective antagonist that acts on presynaptic dopamine autoreceptors; CGP 25454A promotes increased release of dopamine and acetylcholine and has potential applications in research on major depressive disorder.

Duloxetine-D3 hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for the treatment of major depressive disorder and generalized anxiety disorder (GAD). Duloxetine D3 hydrochloride ( (S)-Duloxetine D3 hydrochloride) is a deuterium-labeled Duloxetine hydrochloride (TMSM-3429).

LY2940094 (LY-2940094) decreases ethanol self-administration in animal models. LY2940094 is an effective, selective, and orally available nociceptin receptor antagonist with high affinity (Ki=0.105 nM) and antagonist potency (Kb=0.166 nM).

Gepirone is a selective 5-HT1A agonist that selectively binds to 5-HT1A receptor sites. It is employed as an antidepressant in research studies focused on anxiety and major depressive disorder.

Clomipramine (Clomicalm) is a tricyclic antidepressant (TCA). It is used for the treatment of the panic disorder, obsessive-compulsive disorder, major depressive disorder, and chronic pain. It may decrease the risk of suicide in those over the age of 65. It is similar to Imipramine in that selective inhibition of the serotonin uptake in the brain.

Forvisirvat (SP-624) is an orally active, brain-permeable, and selective activator of the silent information regulator protein 6 (SIRT6). It enhances the deacetylase activity of SIRT6, promotes DNA repair and mitochondrial health, and demonstrates antidepressant effects in animal models. Forvisirvat holds promise for the investigation of major depressive disorder.

Fumiporexant (Compound Example 93) is an orally active, brain-penetrant, and selective antagonist of orexin receptor 2 (OX2R). It regulates the sleep-wake cycle and pathways related to mood in the central nervous system. Fumiporexant holds potential for research into neurological disorders such as insomnia and major depressive disorder.

Trazodone (AF-1161), a 5-HT 2A/2C receptor antagonist, is used as an antidepressant for treating major anxiety disorders and depressive disorder.

ABT-384 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1.

Flerobuterol is a β adrenergic receptor agonist potentially for the treatment of major depressive disorder. Flerobuterol enhances serotonergic neurotransmission. Flerobuterol acutely increases 5-HT synthesis, in part, through an elevation of brain Trp ava

LY-2940094, a nociceptin receptor antagonist, is used potentially for the treatment of major depressive disorder and alcoholism.

(±)-Duloxetine ((Rac)-Duloxetine) hydrochloride is the racemate of Duloxetine hydrochloride and is used in research for diabetic neuropathic pain, fibromyalgia, and major depressive disorder as a serotonin-norepinephrine reuptake inhibitor [1].

Fluvoxamine acid is a medication which functions as a selective serotonin reuptake inhibitor (SSRI) and σ1 receptor agonist. Fluvoxamine is used primarily for the treatment of obsessive-compulsive disorder (OCD), and is also used to treat major depressive disorder (MDD), and anxiety disorders such as panic disorder and post-traumatic stress disorder (PTSD).

EVT-101 free base, also known as ENS-101, is an experimental compound for investigations involving major depressive disorder. EVT-101 free base functions as a selective antagonist of the NMDA receptor subunit 2B (NR2B). EVT-101 free base is applicable to neuropharmacology, glutamatergic neurotransmission, and central nervous system signaling research.

Orvepitant is a potent and selective NK1 antagonist, which may be potentially useful for patients with major depressive disorder (MDD), anxiety and insomnia.

Elzasonan is a selective 5-hydroxytryptamine 1B receptor antagonist used to treat patients with major depressive disorder and obsessive compulsive disorder.

Duloxetine is an inhibitor of serotonin-norepinephrine reuptake(Ki of 4.6 nM),with treatment of major depressive disorder and generalized anxiety disorder.